{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:45:54Z","timestamp":1785329154858,"version":"3.55.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Consumer Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40265-017-0712-6","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:23:47Z","timestamp":1487852627000},"page":"547-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus"],"prefix":"10.1007","volume":"77","author":[{"given":"David A.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip O.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan C.","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Katelaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu I.","family":"Tutuian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald O.","family":"Castell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"issue":"7","key":"712_CR1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1185\/03007995.2015.1047745","volume":"31","author":"HF Boardman","year":"2015","unstructured":"Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin. 2015;31(7):1309\u201318.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"712_CR2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases\u2014a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.","journal-title":"BMC Med."},{"issue":"10","key":"712_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjmed.2009.04.014","volume":"122","author":"T Ali","year":"2009","unstructured":"Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896\u2013903.","journal-title":"Am J Med."},{"key":"712_CR4","unstructured":"Prilosec [package insert]. Wilmington: AstraZeneca Pharmaceuticals; 2012."},{"key":"712_CR5","unstructured":"Prilosec OTC [product monograph]. Cincinnati: Procter & Gamble; 2014."},{"issue":"5","key":"712_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11096-015-0150-z","volume":"37","author":"HF Boardman","year":"2015","unstructured":"Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 2015;37(5):709\u201316.","journal-title":"Int J Clin Pharm."},{"issue":"7","key":"712_CR7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/13611260500069947","volume":"27","author":"MR Villiers de","year":"2005","unstructured":"de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639\u201343.","journal-title":"Med Teach."},{"issue":"1","key":"712_CR8","doi-asserted-by":"crossref","first-page":"e1000393","DOI":"10.1371\/journal.pmed.1000393","volume":"8","author":"IP Sinha","year":"2011","unstructured":"Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011;8(1):e1000393.","journal-title":"PLoS Med."},{"issue":"7650","key":"712_CR9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ."},{"issue":"3","key":"712_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381\u20137.","journal-title":"Gut."},{"issue":"592","key":"712_CR11","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.3399\/bjgp11X606609","volume":"61","author":"J Hippisley-Cox","year":"2011","unstructured":"Hippisley-Cox J, Coupland C. Identifying patients with suspected gastro-oesophageal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011;61(592):e707\u201314.","journal-title":"Br J Gen Pract."},{"issue":"4","key":"712_CR12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2005.07.028","volume":"129","author":"A Lassen","year":"2005","unstructured":"Lassen A, Hallas J, de Muckadell OB. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication. Gastroenterology. 2005;129(4):1179\u201386.","journal-title":"Gastroenterology."},{"issue":"27","key":"712_CR13","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3748\/wjg.v18.i27.3483","volume":"18","author":"R Milind","year":"2012","unstructured":"Milind R, Attwood SE. Natural history of Barrett\u2019s esophagus. World J Gastroenterol. 2012;18(27):3483\u201391.","journal-title":"World J Gastroenterol."},{"issue":"8","key":"712_CR14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","volume":"63","author":"S Singh","year":"2014","unstructured":"Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett\u2019s oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229\u201337.","journal-title":"Gut."},{"issue":"7","key":"712_CR15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/gutjnl-2011-300730","volume":"61","author":"TK Desai","year":"2012","unstructured":"Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett\u2019s oesophagus: a meta-analysis. Gut. 2012;61(7):970\u20136.","journal-title":"Gut."},{"issue":"1","key":"712_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1055-9965.EPI-10-0802","volume":"20","author":"JA Abrams","year":"2011","unstructured":"Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940\u20132007. Cancer Epidemiol Biomark Prev. 2011;20(1):183\u20136.","journal-title":"Cancer Epidemiol Biomark Prev."},{"issue":"11","key":"712_CR17","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","volume":"55","author":"LA Garcia Rodriguez","year":"2006","unstructured":"Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55(11):1538\u201344.","journal-title":"Gut."},{"issue":"7","key":"712_CR18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/gut.52.7.942","volume":"52","author":"DN Bateman","year":"2003","unstructured":"Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, et al. Mortality study of 18 000 patients treated with omeprazole. Gut. 2003;52(7):942\u20136.","journal-title":"Gut."},{"issue":"6","key":"712_CR19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1756283X15592583","volume":"8","author":"P Katz","year":"2015","unstructured":"Katz P, Kahrilas P, Johnson D, Lind T, Rohss K, Traxler B, et al. Daytime intragastric acid control: post hoc analyses of esomeprazole 20\u00a0mg and over-the-counter proton-pump inhibitors. Ther Adv Gastroenterol. 2015;8(6):322\u201330.","journal-title":"Ther Adv Gastroenterol."},{"issue":"6","key":"712_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00044011-200828060-00001","volume":"28","author":"C Wilder-Smith","year":"2008","unstructured":"Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Rohss K. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose\u2013response study. Clin Drug Investig. 2008;28(6):333\u201343.","journal-title":"Clin Drug Investig."},{"issue":"12","key":"712_CR21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1365-2036.1998.00416.x","volume":"12","author":"V Savarino","year":"1998","unstructured":"Savarino V, Mela GS, Zentilin P, Bisso G, Pivari M, Vigneri S, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther. 1998;12(12):1241\u20137.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"712_CR22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"712_CR23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","volume":"42","author":"L Lundell","year":"2015","unstructured":"Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649\u201363.","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"712_CR24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/gut.2005.090514","volume":"55","author":"EJ Kuipers","year":"2006","unstructured":"Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55(9):1217\u201321.","journal-title":"Gut."},{"key":"712_CR25","doi-asserted-by":"crossref","unstructured":"World Gastroenterology Organisation global guideline: Helicobacter pylori in developing countries. J Dig Dis. 2011;12(5):319\u201326.","DOI":"10.1111\/j.1751-2980.2011.00529.x"},{"issue":"1","key":"712_CR26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12253-009-9192-7","volume":"16","author":"H Wong","year":"2010","unstructured":"Wong H, Yau T, Chan P, Ng IO, Chan G, Hui P, et al. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol Oncol Res. 2010;16(1):87\u201391.","journal-title":"Pathol Oncol Res."},{"issue":"26","key":"712_CR27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1056\/NEJM199806253382616","volume":"338","author":"J Wayman","year":"1998","unstructured":"Wayman J, Hayes N, Griffin SM. The response of early gastric cancer to proton-pump inhibitors. N Engl J Med. 1998;338(26):1924\u20135.","journal-title":"N Engl J Med."},{"issue":"4","key":"712_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archfami.9.4.385","volume":"9","author":"J Wayman","year":"2000","unstructured":"Wayman J, Hayes N, Raimes SA, Griffin SM. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med. 2000;9(4):385\u20138.","journal-title":"Arch Fam Med."},{"issue":"3","key":"712_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1385\/IJGC:35:3:211","volume":"35","author":"A Tartaglia","year":"2005","unstructured":"Tartaglia A, Vezzadini C, Bianchini S, Vezzadini P. Gastrinoma of the stomach: a case report. Int J Gastrointest Cancer. 2005;35(3):211\u20136.","journal-title":"Int J Gastrointest Cancer."},{"issue":"7","key":"712_CR30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","volume":"36","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Fossmark R, Viset T, Qvigstad G, Sordal O, Marvik R, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36(7):644\u20139.","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"712_CR31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","volume":"100","author":"AH Poulsen","year":"2009","unstructured":"Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sorensen HT, Olsen JH, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100(9):1503\u20137.","journal-title":"Br J Cancer."},{"issue":"1","key":"712_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/apt.13450","volume":"43","author":"JL Schneider","year":"2016","unstructured":"Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(1):73\u201382.","journal-title":"Aliment Pharmacol Ther."},{"issue":"16","key":"712_CR33","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3748\/wjg.v19.i16.2560","volume":"19","author":"JS Ahn","year":"2013","unstructured":"Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19(16):2560\u20138.","journal-title":"World J Gastroenterol."},{"issue":"8","key":"712_CR34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00002018-200831080-00004","volume":"31","author":"H Tamim","year":"2008","unstructured":"Tamim H, Duranceau A, Chen LQ, Lelorier J. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case\u2013control study. Drug Saf. 2008;31(8):675\u201384.","journal-title":"Drug Saf."},{"issue":"3","key":"712_CR35","first-page":"161","volume":"65","author":"C Meyer","year":"2002","unstructured":"Meyer C, Lozac\u2019h P, Rohr S, Topar P, Youssef C. Gastric cancer: the French survey. Acta Gastroenterol Belg. 2002;65(3):161\u20135.","journal-title":"Acta Gastroenterol Belg."},{"key":"712_CR36","unstructured":"What you need to know about stomach cancer. Rockville: National Cancer Institute; 2009."},{"issue":"4","key":"712_CR37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10120-006-0399-y","volume":"9","author":"H Suzuki","year":"2006","unstructured":"Suzuki H, Gotoda T, Sasako M, Saito D. Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer. 2006;9(4):315\u20139.","journal-title":"Gastric Cancer."},{"issue":"3","key":"712_CR38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11096-011-9489-y","volume":"33","author":"G Holtmann","year":"2011","unstructured":"Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33(3):493\u2013500.","journal-title":"Int J Clin Pharm."},{"issue":"4","key":"712_CR39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000235953","volume":"80","author":"S Haag","year":"2009","unstructured":"Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226\u201334.","journal-title":"Digestion."},{"issue":"7","key":"712_CR40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MCG.0000000000000141","volume":"48","author":"R Hunt","year":"2014","unstructured":"Hunt R, Quigley E, Abbas Z, Eliakim A, Emmanuel A, Goh KL, et al. Coping with common gastrointestinal symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain\/discomfort May 2013. J Clin Gastroenterol. 2014;48(7):567\u201378.","journal-title":"J Clin Gastroenterol."},{"issue":"4","key":"712_CR41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1067\/mge.2002.122617","volume":"55","author":"JC Wu","year":"2002","unstructured":"Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on \u201ctypical\u201d reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection. Gastrointest Endosc. 2002;55(4):461\u20135.","journal-title":"Gastrointest Endosc."},{"issue":"11","key":"712_CR42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1365-2036.2005.02508.x","volume":"21","author":"KY Ho","year":"2005","unstructured":"Ho KY, Gwee KA, Khor CJ, Selamat DS, Wai CT, Yeoh KG. Empirical treatment for the management of patients presenting with uninvestigated reflux symptoms: a prospective study in an Asian primary care population. Aliment Pharmacol Ther. 2005;21(11):1313\u201320.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"712_CR43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2036.2011.04901.x","volume":"35","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, et al. Evolution of gastro-oesophageal reflux disease over 5\u00a0years under routine medical care\u2014the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154\u201364.","journal-title":"Aliment Pharmacol Ther."},{"key":"712_CR44","unstructured":"Coping with common GI symptoms in the community: a global perspective on heartburn, constipation, bloating, and abdominal pain\/discomfort. World Gastroenterology Organisation website. 2013. http:\/\/www.worldgastroenterology.org\/assets\/export\/userfiles\/2013_FINAL_Common%20GI%20Symptoms%20_long.pdf . Accessed 25 May 2016."},{"issue":"3","key":"712_CR45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.13028","volume":"41","author":"SL Chen","year":"2015","unstructured":"Chen SL, Gwee KA, Lee JS, Miwa H, Suzuki H, Guo P, et al. Systematic review with meta-analysis: prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia. Aliment Pharmacol Ther. 2015;41(3):239\u201352.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"712_CR46","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.ejca.2014.01.029","volume":"50","author":"A Ferro","year":"2014","unstructured":"Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980\u20132011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330\u201344.","journal-title":"Eur J Cancer."},{"issue":"6","key":"712_CR47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5946\/ce.2014.47.6.490","volume":"47","author":"KS Choi","year":"2014","unstructured":"Choi KS, Suh M. Screening for gastric cancer: the usefulness of endoscopy. Clin Endosc. 2014;47(6):490\u20136.","journal-title":"Clin Endosc."},{"issue":"2","key":"712_CR48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.gie.2015.04.003","volume":"82","author":"A Shaukat","year":"2015","unstructured":"Shaukat A, Wang A, Acosta RD, Bruining DH, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2015;82(2):227\u201332.","journal-title":"Gastrointest Endosc."},{"issue":"1","key":"712_CR49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/gut.46.1.93","volume":"46","author":"NP Breslin","year":"2000","unstructured":"Breslin NP, Thomson AB, Bailey RJ, Blustein PK, Meddings J, Lalor E, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut. 2000;46(1):93\u20137.","journal-title":"Gut."},{"issue":"7","key":"712_CR50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.cgh.2009.03.031","volume":"7","author":"N Vakil","year":"2009","unstructured":"Vakil N, Talley N, van Zanten SV, Flook N, Persson T, Bjorck E, et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol. 2009;7(7):756\u201361.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"712_CR51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308\u201328.","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"712_CR52","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00464-005-0679-3","volume":"20","author":"DJ Bowrey","year":"2006","unstructured":"Bowrey DJ, Griffin SM, Wayman J, Karat D, Hayes N, Raimes SA. Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. Surg Endosc. 2006;20(11):1725\u20138.","journal-title":"Surg Endosc."},{"issue":"10","key":"712_CR53","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2036.2004.02251.x","volume":"20","author":"GA Fransen","year":"2004","unstructured":"Fransen GA, Janssen MJ, Muris JW, Laheij RJ, Jansen JB. Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther. 2004;20(10):1045\u201352.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"712_CR54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2006.04.029","volume":"131","author":"N Vakil","year":"2006","unstructured":"Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006;131(2):390\u2013401.","journal-title":"Gastroenterology."},{"issue":"5","key":"712_CR55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9343(98)00087-4","volume":"104","author":"B Termanini","year":"1998","unstructured":"Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger\u2013Ellison syndrome. Am J Med. 1998;104(5):422\u201330.","journal-title":"Am J Med."},{"issue":"7","key":"712_CR56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","volume":"118","author":"MB O\u2019Connell","year":"2005","unstructured":"O\u2019Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778\u201381.","journal-title":"Am J Med."},{"issue":"17","key":"712_CR57","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMc066308","volume":"355","author":"M Epstein","year":"2006","unstructured":"Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834\u20136.","journal-title":"N Engl J Med."},{"issue":"4","key":"712_CR58","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.ajkd.2013.02.373","volume":"62","author":"I Koulouridis","year":"2013","unstructured":"Koulouridis I, Alfayez M, Tighiouart H, Madias NE, Kent DM, Paulus JK, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case\u2013control study. Am J Kidney Dis. 2013;62(4):730\u20137.","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"712_CR59","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","volume":"41","author":"SE Attwood","year":"2015","unstructured":"Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162\u201374.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"712_CR60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2036.2008.03601.x","volume":"27","author":"WP Elzen den","year":"2008","unstructured":"den Elzen WP, Groeneveld Y, de Ruijter W, Souverijn JH, Le CS, Assendelft WJ, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008;27(6):491\u20137.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"712_CR61","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1365-2036.2008.03658.x","volume":"27","author":"BI Hirschowitz","year":"2008","unstructured":"Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27(11):1110\u201321.","journal-title":"Aliment Pharmacol Ther."},{"key":"712_CR62","unstructured":"FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). 2011. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245011.htm . Accessed 24 Jan 2017."},{"issue":"1","key":"712_CR63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.00015.2012","volume":"93","author":"S Kopic","year":"2013","unstructured":"Kopic S, Geibel JP. Gastric acid, calcium absorption, and their impact on bone health. Physiol Rev. 2013;93(1):189\u2013268.","journal-title":"Physiol Rev."},{"issue":"2","key":"712_CR64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0005-2736(91)90238-4","volume":"1065","author":"JP Mattsson","year":"1991","unstructured":"Mattsson JP, Vaananen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991;1065(2):261\u20138.","journal-title":"Biochim Biophys Acta."},{"issue":"10","key":"712_CR65","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/jbmr.108","volume":"25","author":"MJ Wright","year":"2010","unstructured":"Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O\u2019Brien KO, Proctor DD, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205\u201311.","journal-title":"J Bone Miner Res."},{"issue":"24","key":"712_CR66","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947\u201353.","journal-title":"JAMA."},{"issue":"1","key":"712_CR67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"DA Corley","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93\u2013101.","journal-title":"Gastroenterology."},{"issue":"9","key":"712_CR68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"SL Gray","year":"2010","unstructured":"Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative. Arch Intern Med. 2010;170(9):765\u201371.","journal-title":"Arch Intern Med."},{"issue":"3","key":"712_CR69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","volume":"138","author":"LE Targownik","year":"2010","unstructured":"Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896\u2013904.","journal-title":"Gastroenterology."},{"issue":"9","key":"712_CR70","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/ajg.2012.200","volume":"107","author":"LE Targownik","year":"2012","unstructured":"Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"712_CR71","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/jbmr.166","volume":"25","author":"KE Hansen","year":"2010","unstructured":"Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786\u201395.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"712_CR72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","volume":"106","author":"S Ngamruengphong","year":"2011","unstructured":"Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209\u201318 (quiz 19).","journal-title":"Am J Gastroenterol."},{"key":"712_CR73","unstructured":"FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Food and Drug Administration. 2011. http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm213206.htm . Accessed 24 Aug 2016."},{"issue":"4","key":"712_CR74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2036.2007.03407.x","volume":"26","author":"F Sierra","year":"2007","unstructured":"Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545\u201353.","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"712_CR75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"ML Blank","year":"2014","unstructured":"Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case\u2013control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837\u201344.","journal-title":"Kidney Int."},{"issue":"1","key":"712_CR76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555-0335","volume":"88","author":"C Dam","year":"2008","unstructured":"Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol. 2008;88(1):87\u20139.","journal-title":"Acta Derm Venereol."},{"issue":"2","key":"712_CR77","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2133.2012.10969.x","volume":"167","author":"CM Gronhagen","year":"2012","unstructured":"Gronhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case\u2013control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296\u2013305.","journal-title":"Br J Dermatol."},{"issue":"1","key":"712_CR78","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0168-8278(00)80201-9","volume":"32","author":"A Rimola","year":"2000","unstructured":"Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142\u201353.","journal-title":"J Hepatol."},{"issue":"4","key":"712_CR79","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jhep.2003.50119","volume":"37","author":"LT Evans","year":"2003","unstructured":"Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology. 2003;37(4):897\u2013901.","journal-title":"Hepatology."},{"issue":"2","key":"712_CR80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gutjnl-2011-300779","volume":"61","author":"R Wiest","year":"2012","unstructured":"Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(2):297\u2013310.","journal-title":"Gut."},{"key":"712_CR81","unstructured":"Arvaniti V, D\u2019Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246\u201356, 56."},{"issue":"2","key":"712_CR82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","volume":"28","author":"A Deshpande","year":"2013","unstructured":"Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235\u201342.","journal-title":"J Gastroenterol Hepatol."},{"issue":"6","key":"712_CR83","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1155\/2014\/751921","volume":"28","author":"M Ratelle","year":"2014","unstructured":"Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2014;28(6):330\u20134.","journal-title":"Can J Gastroenterol Hepatol."},{"issue":"22","key":"712_CR84","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1097\/MD.0000000000000944","volume":"94","author":"SS Chang","year":"2015","unstructured":"Chang SS, Lai CC, Lee MT, Lee YC, Tsai YW, Hsu WT, et al. Risk of spontaneous bacterial peritonitis associated with gastric acid suppression. Medicine (Baltimore). 2015;94(22):e944.","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"712_CR85","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/apt.12875","volume":"40","author":"YW Min","year":"2014","unstructured":"Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695\u2013704.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"712_CR86","doi-asserted-by":"crossref","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.","journal-title":"PLoS One."},{"issue":"3","key":"712_CR87","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","volume":"183","author":"CS Eom","year":"2011","unstructured":"Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310\u20139.","journal-title":"CMAJ."},{"issue":"3","key":"712_CR88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/1817-1737.53347","volume":"4","author":"GS Gaude","year":"2009","unstructured":"Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009;4(3):115\u201323.","journal-title":"Ann Thorac Med."},{"issue":"9","key":"712_CR89","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1155\/2008\/821385","volume":"22","author":"N Sultan","year":"2008","unstructured":"Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22(9):761\u20136.","journal-title":"Can J Gastroenterol."},{"issue":"6","key":"712_CR90","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181b5f27d","volume":"20","author":"LA Garcia Rodriguez","year":"2009","unstructured":"Garcia Rodriguez LA, Ruigomez A, Wallander MA, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology. 2009;20(6):800\u20136.","journal-title":"Epidemiology."},{"issue":"8","key":"712_CR91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2036.2003.01744.x","volume":"18","author":"RJ Laheij","year":"2003","unstructured":"Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18(8):847\u201351.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"712_CR92","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2036.2010.04284.x","volume":"31","author":"J Johnstone","year":"2010","unstructured":"Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165\u201377.","journal-title":"Aliment Pharmacol Ther."},{"issue":"16","key":"712_CR93","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","volume":"292","author":"RJ Laheij","year":"2004","unstructured":"Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955\u201360.","journal-title":"JAMA."},{"issue":"4","key":"712_CR94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gutjnl-2013-304738","volume":"63","author":"KB Filion","year":"2014","unstructured":"Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552\u20138.","journal-title":"Gut."},{"issue":"2","key":"712_CR95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11606-012-2211-5","volume":"28","author":"AB Jena","year":"2013","unstructured":"Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med. 2013;28(2):223\u201330.","journal-title":"J Gen Intern Med."},{"key":"712_CR96","unstructured":"Connor BA. The pre-travel consultation self-treatable conditions: traveler\u2019s diarrhea. 2016 Yellow Book. 2016. http:\/\/www.nc.cdc.gov\/travel\/yellowbook\/2016\/the-pre-travel-consultation\/travelers-diarrhea . Accessed 9 June 2016."},{"issue":"9","key":"712_CR97","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","volume":"102","author":"J Leonard","year":"2007","unstructured":"Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047\u201356.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"712_CR98","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S0950268805005406","volume":"134","author":"Y Doorduyn","year":"2006","unstructured":"Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van PW. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134(3):617\u201326.","journal-title":"Epidemiol Infect."},{"key":"712_CR99","first-page":"1","volume":"2015","author":"R Freeman","year":"2013","unstructured":"Freeman R, Dabrera G, Lane C, Adams N, Browning L, Fowler T, et al. Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella mikawasima in the UK. Epidemiol Infect. 2013;2015:1\u20138.","journal-title":"Epidemiol Infect."},{"issue":"10","key":"712_CR100","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1017\/S095026881000052X","volume":"138","author":"Y Doorduyn","year":"2010","unstructured":"Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Breukink BJ, Wagenaar JA, Van PW. Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case\u2013control study. Epidemiol Infect. 2010;138(10):1391\u2013404.","journal-title":"Epidemiol Infect."},{"issue":"1","key":"712_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197107012850101","volume":"285","author":"HL DuPont","year":"1971","unstructured":"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971;285(1):1\u20139.","journal-title":"N Engl J Med."},{"issue":"11\u201312","key":"712_CR102","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","volume":"34","author":"C Bavishi","year":"2011","unstructured":"Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11\u201312):1269\u201381.","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"712_CR103","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00052-05","volume":"19","author":"DJ Diemert","year":"2006","unstructured":"Diemert DJ. Prevention and self-treatment of traveler\u2019s diarrhea. Clin Microbiol Rev. 2006;19(3):583\u201394.","journal-title":"Clin Microbiol Rev."},{"issue":"1","key":"712_CR104","first-page":"119","volume":"60","author":"G Juckett","year":"1999","unstructured":"Juckett G. Prevention and treatment of traveler\u2019s diarrhea. Am Fam Physician. 1999;60(1):119\u201324.","journal-title":"Am Fam Physician."},{"issue":"11","key":"712_CR105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.13199","volume":"41","author":"J Schwille-Kiuntke","year":"2015","unstructured":"Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers\u2019 diarrhoea. Aliment Pharmacol Ther. 2015;41(11):1029\u201337.","journal-title":"Aliment Pharmacol Ther."},{"key":"712_CR106","unstructured":"Nearly half a million Americans suffered from Clostridium difficile infections in a single year [press release]. 2015. http:\/\/www.cdc.gov\/media\/releases\/2015\/p0225-clostridium-difficile.html . Accessed 24 Aug 2016."},{"issue":"9","key":"712_CR107","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825\u201334.","journal-title":"N Engl J Med."},{"issue":"6","key":"712_CR108","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2036.2008.03924.x","volume":"29","author":"BR Dalton","year":"2009","unstructured":"Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther. 2009;29(6):626\u201334.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"712_CR109","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"712_CR110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ajg.2015.22","volume":"110","author":"IM Zacharioudakis","year":"2015","unstructured":"Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(3):381\u201390.","journal-title":"Am J Gastroenterol."},{"key":"712_CR111","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2049-2618-2-42","volume":"2","author":"CT Seto","year":"2014","unstructured":"Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.","journal-title":"Microbiome."},{"issue":"8","key":"712_CR112","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/AAC.01443-06","volume":"51","author":"RL Jump","year":"2007","unstructured":"Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"712_CR113","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.gastro.2015.06.043","volume":"149","author":"DE Freedberg","year":"2015","unstructured":"Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883\u20135.","journal-title":"Gastroenterology."},{"key":"712_CR114","unstructured":"FDA drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm290510.htm . Accessed 24 Aug 2016."},{"issue":"6","key":"712_CR115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/qjmed\/hcn035","volume":"101","author":"MN Choudhry","year":"2008","unstructured":"Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445\u20138.","journal-title":"QJM."},{"issue":"9","key":"712_CR116","first-page":"e228","volume":"16","author":"JJ Heidelbaugh","year":"2010","unstructured":"Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228\u201334.","journal-title":"Am J Manag Care."},{"issue":"12","key":"712_CR117","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2003.01600.x","volume":"17","author":"F Parente","year":"2003","unstructured":"Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther. 2003;17(12):1503\u20136.","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"712_CR118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"RS Wedemeyer","year":"2014","unstructured":"Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201\u201311.","journal-title":"Drug Saf."},{"issue":"4","key":"712_CR119","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","volume":"17","author":"S Bezabeh","year":"2012","unstructured":"Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug\u2013drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550\u20134.","journal-title":"Oncologist."},{"issue":"7","key":"712_CR120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1468-1293.2007.00496.x","volume":"8","author":"AD Luber","year":"2007","unstructured":"Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I. Steady-state pharmacokinetics of once-daily fosamprenavir\/ritonavir and atazanavir\/ritonavir alone and in combination with 20\u00a0mg omeprazole in healthy volunteers. HIV Med. 2007;8(7):457\u201364.","journal-title":"HIV Med."},{"issue":"6","key":"712_CR121","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1468-1293.2007.00482.x","volume":"8","author":"L Beique","year":"2007","unstructured":"Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med. 2007;8(6):335\u201345.","journal-title":"HIV Med."},{"issue":"10","key":"712_CR122","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1345\/aph.1H217","volume":"40","author":"EG Sahloff","year":"2006","unstructured":"Sahloff EG, Duggan JM. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Ann Pharmacother. 2006;40(10):1731\u20136.","journal-title":"Ann Pharmacother."},{"key":"712_CR123","unstructured":"Harvoni [summary of product characteristics]. London: Gilead Sciences; 2015."},{"issue":"4","key":"712_CR124","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","volume":"10","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10(4):264\u201371.","journal-title":"Am J Geriatr Pharmacother."},{"issue":"1","key":"712_CR125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","volume":"37","author":"C Gjestad","year":"2015","unstructured":"Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90\u20137.","journal-title":"Ther Drug Monit."},{"issue":"3","key":"712_CR126","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcp.12384","volume":"78","author":"DJ Reeves","year":"2014","unstructured":"Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565\u201371.","journal-title":"Br J Clin Pharmacol."},{"issue":"12","key":"712_CR127","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2036.2009.03993.x","volume":"29","author":"E Lahner","year":"2009","unstructured":"Lahner E, Annibale B, Delle FG. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009;29(12):1219\u201329.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"712_CR128","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1600-6143.2009.02682.x","volume":"9","author":"S Kofler","year":"2009","unstructured":"Kofler S, Shvets N, Bigdeli AK, Konig MA, Kaczmarek P, Deutsch MA, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case\u2013controlled study. Am J Transplant. 2009;9(7):1650\u20136.","journal-title":"Am J Transplant."},{"issue":"6","key":"712_CR129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.healun.2009.03.006","volume":"28","author":"S Kofler","year":"2009","unstructured":"Kofler S, Deutsch MA, Bigdeli AK, Shvets N, Vogeser M, Mueller TH, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605\u201311.","journal-title":"J Heart Lung Transplant."},{"issue":"10","key":"712_CR130","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/0091270009344988","volume":"49","author":"K Rupprecht","year":"2009","unstructured":"Rupprecht K, Schmidt C, Raspe A, Schweda F, Shipkova M, Fischer W, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196\u2013201.","journal-title":"J Clin Pharmacol."},{"issue":"11","key":"712_CR131","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","volume":"49","author":"M Schaier","year":"2010","unstructured":"Schaier M, Scholl C, Scharpf D, Hug F, Bonisch-Schmidt S, Dikow R, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061\u20137.","journal-title":"Rheumatology (Oxford)."},{"issue":"5","key":"712_CR132","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1345\/aph.1D366","volume":"38","author":"K Takahashi","year":"2004","unstructured":"Takahashi K, Motohashi H, Yonezawa A, Okuda M, Ito N, Yamamoto S, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38(5):791\u20134.","journal-title":"Ann Pharmacother."},{"issue":"8","key":"712_CR133","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1211\/0022357043914","volume":"56","author":"F Itagaki","year":"2004","unstructured":"Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56(8):1055\u20139.","journal-title":"J Pharm Pharmacol."},{"issue":"7","key":"712_CR134","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/S0041-1345(02)03409-7","volume":"34","author":"F Itagaki","year":"2002","unstructured":"Itagaki F, Homma M, Yuzawa K, Fukao K, Kohda Y. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc. 2002;34(7):2777\u20138.","journal-title":"Transplant Proc."},{"issue":"1","key":"712_CR135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MJT.0b013e31829c4c71","volume":"22","author":"S Kim","year":"2015","unstructured":"Kim S, Lee H, Park CH, Shim CN, Lee HJ, Park JC, et al. Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther. 2015;22(1):14\u201321.","journal-title":"Am J Ther."},{"issue":"1","key":"712_CR136","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","volume":"67","author":"K Suzuki","year":"2009","unstructured":"Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44\u20139.","journal-title":"Br J Clin Pharmacol."},{"key":"712_CR137","unstructured":"Methotrexate safety information. Food and Drug Administration. 2011. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm284421.htm . Accessed 24 Aug 2016."},{"issue":"2","key":"712_CR138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1078155213482602","volume":"20","author":"AJ Chan","year":"2014","unstructured":"Chan AJ, Rajakumar I. High-dose methotrexate in adult oncology patients: a case\u2013control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract. 2014;20(2):93\u20139.","journal-title":"J Oncol Pharm Pract."},{"issue":"20","key":"712_CR139","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909\u201317.","journal-title":"N Engl J Med."},{"issue":"1","key":"712_CR140","doi-asserted-by":"crossref","first-page":"e000248","DOI":"10.1136\/openhrt-2015-000248","volume":"2","author":"RN Cardoso","year":"2015","unstructured":"Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248.","journal-title":"Open Heart."},{"key":"712_CR141","doi-asserted-by":"crossref","first-page":"h5096","DOI":"10.1136\/bmj.h5096","volume":"351","author":"AM Schjerning Olsen","year":"2015","unstructured":"Schjerning Olsen AM, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbol E, et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015;351:h5096.","journal-title":"BMJ."},{"key":"712_CR142","first-page":"449","volume":"11","author":"ZY Wang","year":"2015","unstructured":"Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449\u201367.","journal-title":"Ther Clin Risk Manag."},{"issue":"11","key":"712_CR143","doi-asserted-by":"crossref","first-page":"e002245","DOI":"10.1161\/JAHA.115.002245","volume":"4","author":"MW Sherwood","year":"2015","unstructured":"Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11):e002245.","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"712_CR144","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2010.11.056","volume":"140","author":"PI Hsu","year":"2011","unstructured":"Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140(3):791\u20138.","journal-title":"Gastroenterology."},{"issue":"7","key":"712_CR145","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","volume":"108","author":"JS Hulot","year":"2006","unstructured":"Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244\u20137.","journal-title":"Blood."},{"issue":"8","key":"712_CR146","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"XQ Li","year":"2004","unstructured":"Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821\u20137.","journal-title":"Drug Metab Dispos."},{"issue":"14","key":"712_CR147","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","volume":"59","author":"AL Frelinger III","year":"2012","unstructured":"Frelinger AL III, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304\u201311.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"712_CR148","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/clc.22117","volume":"36","author":"Y Arbel","year":"2013","unstructured":"Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, et al. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study. Clin Cardiol. 2013;36(6):342\u20136.","journal-title":"Clin Cardiol."},{"issue":"8","key":"712_CR149","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","volume":"128","author":"YT Ghebremariam","year":"2013","unstructured":"Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845\u201353.","journal-title":"Circulation."},{"issue":"6","key":"712_CR150","doi-asserted-by":"crossref","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","volume":"10","author":"NH Shah","year":"2015","unstructured":"Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653.","journal-title":"PLoS One."},{"issue":"6","key":"712_CR151","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","volume":"153","author":"M Charlot","year":"2010","unstructured":"Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378\u201386.","journal-title":"Ann Intern Med."},{"issue":"1","key":"712_CR152","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijcard.2014.09.036","volume":"177","author":"CJ Shih","year":"2014","unstructured":"Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292\u20137.","journal-title":"Int J Cardiol."},{"issue":"1","key":"712_CR153","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00228-014-1779-6","volume":"71","author":"A Turkiewicz","year":"2015","unstructured":"Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction\u2014a case-crossover analysis. Eur J Clin Pharmacol. 2015;71(1):125\u20139.","journal-title":"Eur J Clin Pharmacol."},{"issue":"11","key":"712_CR154","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/j.1572-0241.2007.01452.x","volume":"102","author":"E Rey","year":"2007","unstructured":"Rey E, Rodriguez-Artalejo F, Herraiz MA, Sanchez P, Alvarez-Sanchez A, Escudero M, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol. 2007;102(11):2395\u2013400.","journal-title":"Am J Gastroenterol."},{"key":"712_CR155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-12-131","volume":"12","author":"SF Malfertheiner","year":"2012","unstructured":"Malfertheiner SF, Malfertheiner MV, Kropf S, Costa SD, Malfertheiner P. A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol. 2012;12:131.","journal-title":"BMC Gastroenterol."},{"issue":"9","key":"712_CR156","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2005.02654.x","volume":"22","author":"JE Richter","year":"2005","unstructured":"Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749\u201357.","journal-title":"Aliment Pharmacol Ther."},{"key":"712_CR157","unstructured":"Dexilant [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2015."},{"issue":"2","key":"712_CR158","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11597290-000000000-00000","volume":"72","author":"R Majithia","year":"2012","unstructured":"Majithia R, Johnson DA. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. Drugs. 2012;72(2):171\u20139.","journal-title":"Drugs."},{"issue":"22","key":"712_CR159","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1002689","volume":"363","author":"B Pasternak","year":"2010","unstructured":"Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114\u201323.","journal-title":"N Engl J Med."},{"issue":"6","key":"712_CR160","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/ajg.2009.122","volume":"104","author":"SK Gill","year":"2009","unstructured":"Gill SK, O\u2019Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104(6):1541\u20135.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"712_CR161","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/1998\/167174","volume":"12","author":"JK Marshall","year":"1998","unstructured":"Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol. 1998;12(3):225\u20137.","journal-title":"Can J Gastroenterol."},{"key":"712_CR162","unstructured":"Prevacid 24HR [drug facts label]. Parsippany: Novartis Consumer Health Inc; 2014."},{"key":"712_CR163","unstructured":"Nexium 24HR [product labeling]. Madison: Pfizer Consumer Healthcare; 2014."},{"issue":"1","key":"712_CR164","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.2006.03129.x","volume":"25","author":"PB Miner Jr","year":"2007","unstructured":"Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6\u00a0mg (Prilosec OTC) o.m. famotidine 10\u00a0mg (Pepcid AC) b.d. and famotidine 20\u00a0mg b.d. over 14\u00a0days of treatment. Aliment Pharmacol Ther. 2007;25(1):103\u20139.","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"712_CR165","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2012.07.010","volume":"37","author":"S Hata","year":"2013","unstructured":"Hata S, Arai M, Maruoka D, Tanaka T, Matsumura T, Suzuki T, et al. Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study. Clin Res Hepatol Gastroenterol. 2013;37(3):296\u2013301.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"2","key":"712_CR166","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2004.00620.x","volume":"30","author":"LD Allgood","year":"2005","unstructured":"Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6\u00a0mg) to placebo for 14\u00a0days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105\u201312.","journal-title":"J Clin Pharm Ther."},{"issue":"4","key":"712_CR167","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","volume":"121","author":"PR Kushner","year":"2009","unstructured":"Kushner PR, Snoddy AM, Gilderman L, Peura DA. Lansoprazole 15\u00a0mg once daily for 14\u00a0days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121(4):67\u201375.","journal-title":"Postgrad Med."},{"issue":"4","key":"712_CR168","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinthera.2010.03.020","volume":"32","author":"S Haag","year":"2010","unstructured":"Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20\u00a0mg once daily with nizatidine or ranitidine 150\u00a0mg twice daily. Clin Ther. 2010;32(4):678\u201390.","journal-title":"Clin Ther."},{"issue":"5","key":"712_CR169","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","volume":"30","author":"DA Peura","year":"2009","unstructured":"Peura DA, Riff DS, Snoddy AM, Fennerty MB. Clinical trial: lansoprazole 15 or 30\u00a0mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther. 2009;30(5):459\u201368.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"712_CR170","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner Jr","year":"2002","unstructured":"Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"712_CR171","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2014.07.2781","volume":"126","author":"DA Peura","year":"2014","unstructured":"Peura DA, Traxler B, Kocun C, Lind T. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014;126(4):33\u201341.","journal-title":"Postgrad Med."},{"issue":"12","key":"712_CR172","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1046\/j.1365-2036.2003.01496.x","volume":"17","author":"D Pantoflickova","year":"2003","unstructured":"Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507\u201314.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"712_CR173","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1365-2036.2012.05086.x","volume":"35","author":"J Tack","year":"2012","unstructured":"Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35(11):1257\u201366.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"712_CR174","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archinte.161.1.45","volume":"161","author":"C Farup","year":"2001","unstructured":"Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161(1):45\u201352.","journal-title":"Arch Intern Med."},{"issue":"11","key":"712_CR175","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1023\/A:1012363501101","volume":"46","author":"SD Mathias","year":"2001","unstructured":"Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci. 2001;46(11):2416\u201323.","journal-title":"Dig Dis Sci."},{"issue":"8","key":"712_CR176","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1365-2036.2003.01770.x","volume":"18","author":"M Kulig","year":"2003","unstructured":"Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease\u2014an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18(8):767\u201376.","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"712_CR177","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1185\/03007995.2014.991818","volume":"31","author":"DA Johnson","year":"2015","unstructured":"Johnson DA, Le Moigne A, Hugo V, Nagy P. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20\u00a0mg in 2 randomized, double-blind, controlled trials. Curr Med Res Opin. 2015;31(2):243\u201350.","journal-title":"Curr Med Res Opin."},{"key":"712_CR178","unstructured":"Nexium Control (esomeprazole) [summary of product characteristics]. Kent: Pfizer Consumer Healthcare Ltd.; 2014."},{"issue":"1","key":"712_CR179","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1542-3565(03)00287-8","volume":"2","author":"AM Fendrick","year":"2004","unstructured":"Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004;2(1):17\u201321.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"712_CR180","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2006.02811.x","volume":"23","author":"JF Bretagne","year":"2006","unstructured":"Bretagne JF, Honnorat C, Richard-Molard B, Caekaert A, Barthelemy P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23(5):607\u201316.","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"712_CR181","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081626","volume":"70","author":"E Rey","year":"2004","unstructured":"Rey E, Moreno-Elola-Olaso C, Rodriguez-Artalejo F, Diaz-Rubio M. Medical consultation for gastro-oesophageal reflux symptoms: reasons and associated factors. Digestion. 2004;70(3):173\u20137.","journal-title":"Digestion."},{"issue":"4","key":"712_CR182","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/AOG.0b013e31826af61a","volume":"120","author":"DA Grimes","year":"2012","unstructured":"Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol. 2012;120(4):920\u20137.","journal-title":"Obstet Gynecol."},{"issue":"4","key":"712_CR183","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"712_CR184","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Int Med. 2016;176(2):238\u201346.","journal-title":"JAMA Int Med."},{"issue":"4","key":"712_CR185","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410\u20136.","journal-title":"JAMA Neurol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0712-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:29:04Z","timestamp":1589732944000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0712-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":185,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0712-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}